Welcome to our dedicated page for NEUROCRINE BIOSCIENCES SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences, Inc. will hold its 2026 annual stockholders’ meeting on May 27, 2026 at 10:30 a.m. in San Diego. Stockholders of record as of March 31, 2026, when 100,581,991 common shares were outstanding, may vote.
They are being asked to elect three Class III directors, cast an advisory vote on executive compensation, and approve an amendment to the 2025 Equity Incentive Plan that would increase shares reserved for issuance by 4,000,000. Investors will also vote on ratifying Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends voting “for” all four proposals and highlights a range of governance practices, including proxy access, a clawback policy, and a classified board structure.
Neurocrine Biosciences agreed to acquire Soleno Therapeutics via a cash tender offer at $53.00 per share, valuing Soleno’s equity at $2.9 billion. The price reflects a 34% premium to Soleno’s April 2, 2026 close and a 51% premium to its 30‑day VWAP. After the tender offer, any remaining Soleno shares will be converted into the same cash amount through a follow‑on merger, making Soleno a wholly owned Neurocrine subsidiary.
The deal is funded with cash on hand plus modest pre‑payable debt and is not subject to a financing condition, but it requires a majority of Soleno shares to be tendered and clearance under the Hart‑Scott‑Rodino Act. Soleno must observe no‑shop restrictions, with a $95.25 million termination fee if it moves to a superior proposal and a $141.5 million reverse termination fee payable by Neurocrine if certain antitrust conditions are not met. Neurocrine highlights Soleno’s VYKAT XR, which generated $190 million of 2025 revenue, as a way to expand its endocrinology and rare‑disease portfolio and add a third first‑in‑class commercial medicine.
Neurocrine Biosciences (NBIX) ownership update: The Vanguard Group filed Amendment No. 10 to its Schedule 13G/A stating it reports beneficial ownership of 0 shares of Neurocrine Biosciences common stock, representing 0%. The filing explains that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report holdings separately on a disaggregated basis in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, and affirms Vanguard (including related investment companies and managed accounts) has rights to receive dividends or sale proceeds for reported securities where applicable.
Neurocrine Biosciences executive Andrew Ratz has reported his initial equity holdings as Chief Technical Operations Officer. The Form 3 shows direct ownership of 1,018 shares of common stock and several equity awards that may convert into additional shares over time.
He holds restricted stock units tied to 3,997 and 5,640 underlying shares of common stock, which vest in annual installments through February 2029 and February 2030. He also holds incentive and non-qualified stock options covering 2,664 and 17,724 shares at an exercise price of $150.10 expiring in 2035, and 805 and 31,348 shares at $124.12 expiring in 2036, subject to monthly vesting schedules. These awards represent potential future ownership if vesting and exercise conditions are met.
Neurocrine Biosciences’ Chief Financial Officer Matt Abernethy reported a charitable stock gift. On March 4, 2026, he transferred 2,249 shares of Neurocrine Biosciences common stock as a bona fide gift, with no value received and no market transaction involved.
After this disposition, he directly holds 42,808 shares of common stock, which include 176 shares purchased on February 27, 2026 under the company’s 2018 Employee Stock Purchase Plan.
Neurocrine Biosciences Chief Scientific Officer makes charitable stock gift
Neurocrine Biosciences’ Chief Scientific Officer, Jude Onyia, reported a bona fide gift of 3,110 shares of common stock effective February 20, 2026. The filing states this was a gift/charitable contribution, not a market transaction, so no price or proceeds were involved. After the transfer, Onyia directly holds 25,670 shares of Neurocrine Biosciences common stock.
ABERNETHY MATT reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 84,802 shares at a weighted average price of $123.99 per share. Following the reported transactions, holdings were 4,484 shares.
Boyer David W. reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 64,637 shares at a weighted average price of $124.01 per share. Following the reported transactions, holdings were 3,083 shares.
Gano Kyle reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 174,989 shares at a weighted average price of $123.87 per share. Following the reported transactions, holdings were 4,484 shares.